Cooperative Agreement UG3HL175041
Award Date
9/1/24
Completion Date
8/31/25
Dollars Obligated
$866K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.837
Assistance Type
Cooperative Agreement
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $742,984 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct a 24-week, blinded, placebo-controlled, randomized Phase II clinical trial. The trial will evaluate whether 10 mg of empagliflozin taken daily can improve right ventricular function and other outcomes in patients with...
The University of Washington was awarded a $1,947,532.70 Project Grant by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct a Phase 2, single-center, randomized, placebo-controlled trial evaluating the safety and clinical efficacy of a 24-week course of the angiotensin receptor blocker valsartan in adults with pulmonary arterial hypertension (PAH). The primary endpoint is change in 6-minute walk distance at 24 weeks, with secondary...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $455,826 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Albert Einstein College of Medicine in Bronx, NY. The 5-year grant, running from January 1, 2025 to December 31, 2029, will fund a double-blind, randomized, placebo-controlled trial to determine the effects of chronic sildenafil administration on vascular remodeling in patients receiving left ventricular assist device (LVAD) therapy. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $691,326 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Northwestern University to develop a "4D Right-Heart Virtual Catheter (4D VCATH)". This novel technology combines advanced mathematical modeling and 4D flow MRI to provide a comprehensive, non-invasive hemodynamic analysis of the right heart chambers. The project aims to enable streamlined diagnosis, classification, and prognosis...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,806,634 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, San Diego to study the NOTCH3 extracellular domain (NOTCH3 ECD) as a serum biomarker for pulmonary arterial hypertension (PAH). The goal is to determine if NOTCH3 ECD levels in patient serum can reliably predict PAH disease progression and severity, regardless of drug regimens. The research aims to develop a simple blood test...
This $658,885 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to advance the fundamental understanding of the molecular mechanisms governing the development of pulmonary arterial hypertension (PAH). The research will utilize a combination of pulmonary arterial endothelial cell cultures and animal PAH models to: Determine how the protein factor Response Gene to Complement 32 (RGC-32) regulates...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,617,792 to The Leland Stanford Junior University (Stanford University) to study the role of the carboxylesterase 1 (CES1) enzyme in the pathogenesis of pulmonary arterial hypertension (PAH). The research aims to determine how loss of CES1 leads to metabolic reprogramming, lipotoxicity, and oxidative stress in pulmonary...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $760,708 to investigate the role of alternative polyadenylation (APA) in right ventricular (RV) fibrosis associated with pulmonary hypertension. The research aims to: Investigate the impact of the APA regulator CPSF6 depletion on the 3' UTR landscape and profibrotic gene expression in RV failure. Uncover the mechanism underlying CPSF6...
This $102,932 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify clinically accessible metrics that can serve as surrogates for right ventricular-pulmonary arterial (RV-PA) coupling and indicators of RV adaptation in pulmonary arterial hypertension (PAH). The proposed research aims to: 1) develop a multivariable model to identify clinically available metrics as...
This $2,130,422 project grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a comprehensive evaluation of lean muscle mass in patients with pulmonary arterial hypertension (PAH). The research project aims to: Characterize the endophenotype of PAH patients with low lean mass and identify the metabolomic signature associated with low lean mass, which may provide insight into novel pathways. Assess...